Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 1:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 362 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Reference product Clear all
Completed Phase 3 Interventional Results available

A Study of Equivalence of Generic Ingenol Mebutate Gel 0.05% and Picato Gel 0.05% in Subjects With Actinic Keratosis

NCT02654769
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Ingenol Mebutate (Picato®), Generic Ingenol Mebutate, Vehicle Foam
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 95 Years
Enrollment
441 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
22
States / cities
Fremont, California • San Diego, California • Aventura, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Oct 31, 2026, 1:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Topiramate Tablets Under Fasted Conditions

NCT00939692
View directory record Official record
Conditions
Healthy
Interventions
Topiramate
Drug
Lead sponsor
Torrent Pharmaceuticals Limited
Industry
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 16, 2013 · Synced Oct 31, 2026, 1:12 PM EDT
Terminated Phase 3 Interventional Results available

REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer

NCT03515629
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
REGN2810/ipi, REGN2810/chemo/ipi, Pembrolizumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Nov 16, 2022 · Synced Oct 31, 2026, 1:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluate Effects of Sprinkled Format REDUCOSE in a Carbohydrate-rich, Mixed Meal on Post-prandial Glycemia

NCT04877366
View directory record Official record
Conditions
Dietary Supplement
Interventions
Dietary Supplement: Sprinkled Format REDUCOSE., Reference control, Active comparator
Dietary Supplement · Other
Lead sponsor
Société des Produits Nestlé (SPN)
Industry
Eligibility
19 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 31, 2026, 1:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Validation of a Diagnostic Test for Glucose-6-phosphate Dehydrogenase (G6PD) Deficiency in Anti-coagulated Blood

NCT04054661
View directory record Official record
Conditions
G6PD Deficiency
Interventions
SD Biosensor STANDARD G6PD Test, Pointe Scientific Test Kit, HemoCue System
Diagnostic Test
Lead sponsor
PATH
Other
Eligibility
18 Years to 65 Years
Enrollment
229 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Reading, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 31, 2026, 1:12 PM EDT
Completed Not applicable Interventional Results available

Performance of an Investigational Blood Glucose Monitoring System in a Clinical Setting

NCT01268488
View directory record Official record
Conditions
Diabetes
Interventions
Ninja 2 Investigational Blood Glucose Meter
Device
Lead sponsor
Ascensia Diabetes Care
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Fairfield, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 3, 2016 · Synced Oct 31, 2026, 1:12 PM EDT
Completed Phase 3 Interventional Results available

To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Secondarily Infected Traumatic Skin Lesions

NCT04155203
View directory record Official record
Conditions
Secondarily Infected Traumatic Skin Lesions
Interventions
Mupirocin Calcium, Vehicle
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
18 Months and older
Enrollment
657 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Oct 31, 2026, 1:12 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of Equivalence of Generic Pimecrolimus Cream 1% and Elidel® 1% in Subjects With Mild to Moderate Atopic Dermatitis

NCT02791308
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Pimecrolimus Cream 1% (Valeant), Vehicle cream, Pimecrolimus Cream, 1%
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
12 Years to 90 Years
Enrollment
587 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
53
States / cities
Anniston, Alabama • Birmingham, Alabama • Mesa, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated May 29, 2020 · Synced Oct 31, 2026, 1:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Comparison of Two KADIAN 10 mg Capsules to a KADIAN 20 mg Capsule Under Fed Conditions

NCT00759915
View directory record Official record
Conditions
Healthy
Interventions
morphine sulfate extended-release capsules, KADIAN (morphine sulfate extended-release) capsules
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2010 · Synced Oct 31, 2026, 1:12 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Propranolol/Carvedilol Versus Atenolol/Bisoprolol/Sotalol

NCT05794997
View directory record Official record
Conditions
Hypertension
Interventions
Propranolol or Carvedilol, Atenolol, Bisoprolol or Sotalol
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
65 Years and older
Enrollment
817,337 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 31, 2026, 1:12 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KSHN001034 in Healthy Postmenopausal Female Volunteers

NCT06995482
View directory record Official record
Conditions
Healthy Postmenopausal Women
Interventions
KSHN001034, Fulvestrant
Drug
Lead sponsor
Kashiv BioSciences, LLC
Industry
Eligibility
45 Years to 60 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Miami Lakes, Florida
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 31, 2026, 1:12 PM EDT
Completed Phase 1 Interventional

A Study of DOXIL/CAELYX in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer

NCT02081495
View directory record Official record
Conditions
Neoplasms
Interventions
DOXIL/CAELYX reference product (Treatment A), DOXIL/CAELYX test product (Treatment B)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 11, 2016 · Synced Oct 31, 2026, 1:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A 26-week Extension of the ZRHR-ERS-09-US Study Evaluating Biological and Functional Changes in Healthy Smokers After Switching to THS 2.2

NCT02649556
View directory record Official record
Conditions
Smoking
Interventions
THS 2.2, CC
Other
Lead sponsor
Philip Morris Products S.A.
Industry
Eligibility
30 Years and older
Enrollment
672 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
19
States / cities
Tempe, Arizona • Clearwater, Florida • Daytona Beach, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2020 · Synced Oct 31, 2026, 1:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Safe and Effective Delivery of Supplemental Iron to Healthy Volunteers

NCT03212677
View directory record Official record
Conditions
Iron
Interventions
Ferrous sulfate, IHAT, Aspiron, Placebo
Dietary Supplement · Other
Lead sponsor
Tufts University
Other
Eligibility
50 Years to 80 Years
Enrollment
226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 25, 2025 · Synced Oct 31, 2026, 1:12 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Scleroderma: Cyclophosphamide or Transplantation

NCT00114530
View directory record Official record
Conditions
Scleroderma, Systemic, Sclerosis, Autoimmune Disease
Interventions
mHSCT, cyclophosphamide
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 69 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
15
States / cities
Duarte, California • Los Angeles, California • Lexington, Kentucky + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Oct 31, 2026, 1:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Bioequivalence of Vycavert (10 mg Hydrocodone Bitartrate/325 mg Acetaminophen) Compared to the Reference Drug Norco

NCT01456520
View directory record Official record
Conditions
Healthy
Interventions
Vycavert, Norco
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 8, 2012 · Synced Oct 31, 2026, 1:12 PM EDT
Completed Phase 2 Interventional

Study of ACT-129968 in Adult Patients With Seasonal Allergic Rhinitis

NCT01241214
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
ACT-129968, Cetirizine, Placebo
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years to 70 Years
Enrollment
579 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
7
States / cities
Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 15, 2019 · Synced Oct 31, 2026, 1:12 PM EDT
Not listed Phase 1 Interventional

A Crossover Bioequivalence Study of Intravenously Administered ATI0918 and DOXIL/CAELYX in Patients With Ovarian Cancer

NCT01715168
View directory record Official record
Conditions
Ovarian Cancer, Malignant Female Reproductive System Neoplasm, Cancer, Ovarian Tumor, Ovarian Epithelial Cancer Recurrent
Interventions
DOXIL/CAELYX, ATI-0918
Drug
Lead sponsor
Azaya Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Yakima, Washington
Source: ClinicalTrials.gov public record
Updated Jan 15, 2015 · Synced Oct 31, 2026, 1:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

To Evaluate the Efficacy of an Experimental Dissolvable Strip in Rapidly Relieving Dentinal Hypersensitivity (DH)

NCT02937623
View directory record Official record
Conditions
Dentin Sensitivity
Interventions
Dissolvable polymer strip containing Novamin (calcium sodium phosphosilicate)
Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jan 29, 2018 · Synced Oct 31, 2026, 1:12 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Postoperative Analgesia in Subjects Undergoing Hemorrhoidectomy

NCT00744848
View directory record Official record
Conditions
Hemorrhoids
Interventions
Bupivacaine HCl, SKY0402
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
20
States / cities
Birmingham, Alabama • Montgomery, Alabama • Pasadena, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2013 · Synced Oct 31, 2026, 1:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Oxycodone Hydrochloride 15 mg Tablets and Roxicodone™ 15 mg Tablets

NCT00853320
View directory record Official record
Conditions
Healthy
Interventions
Oxycodone hydrochloride tablet 15 mg, Roxicodone™ tablet 15 mg
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 19, 2016 · Synced Oct 31, 2026, 1:12 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study Evaluating Quality of Life Parameters Following Use of Emergen-C

NCT06654089
View directory record Official record
Conditions
Dietary Supplements
Interventions
Emergen-C Core Super Orange Powder, Placebo
Dietary Supplement
Lead sponsor
HALEON
Industry
Eligibility
18 Years to 64 Years
Enrollment
299 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 31, 2026, 1:12 PM EDT
Completed Phase 3 Interventional Results available

Comparative Safety and Efficacy of Two Antiviral Treatments in the Treatment of Recurrent Herpes Simplex Labialis

NCT02265913
View directory record Official record
Conditions
Herpes Labialis
Interventions
Acyclovir 5 percent (Perrigo), Acyclovir 5 percent (Reference), Placebo cream
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
12 Years and older
Enrollment
4,076 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 22, 2021 · Synced Oct 31, 2026, 1:12 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Clinical Endpoint Bioequivalence Study of "Oxymetazoline Hydrochloride Cream"

NCT03954444
View directory record Official record
Conditions
Rosacea
Interventions
Oxymetazoline Hydrochloride, Rhofade Cream, 1%, Placebo
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Lynchburg, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Oct 31, 2026, 1:12 PM EDT